{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2023"],"submitter":["Miller KM"],"pubmed_abstract":["<h4>Objective</h4>To further evaluate glycemic outcomes during the observational extension phase of the Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). <i>Subjects and Methods</i>. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents and young adults aged 14 to <25 years old with suboptimally controlled type 1 diabetes, 70 (89%) participants in the BGM group initiated use of CGM (referred to as BGM-CGM cohort), and 70 (95%) participants in the CGM group continued to use of CGM (CGM-CGM cohort) for an additional 26 weeks.<h4>Results</h4>In the CGM-CGM cohort, mean hemoglobin A1c (HbA1c) decreased from 8.9% ± 0.9% (74 ± 9.8 mmol/mol) at randomization to 8.3% ± 1.3% (67 ± 14.2 mmol/mol) at 52 "],"journal":["Pediatric diabetes"],"pagination":["6718115"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12016685"],"repository":["biostudies-literature"],"pubmed_title":["Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results."],"pmcid":["PMC12016685"],"pubmed_authors":["Kanapka LG","Willi SM","Clements MA","Williams K","for the CITY Study Group","Laffel LM","Lyons SK","Bauza C","Hood K","Prahalad P","Freiner E","Moore W","DeSalvo DJ","Messer LH","Criego A","Simmons JH","Sulik M","Weinstock RS","Bergamo K","Miller KM","Monzavi R","Wadwa RP","Sherr J"],"additional_accession":[]},"is_claimable":false,"name":"Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results.","description":"<h4>Objective</h4>To further evaluate glycemic outcomes during the observational extension phase of the Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). <i>Subjects and Methods</i>. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents and young adults aged 14 to <25 years old with suboptimally controlled type 1 diabetes, 70 (89%) participants in the BGM group initiated use of CGM (referred to as BGM-CGM cohort), and 70 (95%) participants in the CGM group continued to use of CGM (CGM-CGM cohort) for an additional 26 weeks.<h4>Results</h4>In the CGM-CGM cohort, mean hemoglobin A1c (HbA1c) decreased from 8.9% ± 0.9% (74 ± 9.8 mmol/mol) at randomization to 8.3% ± 1.3% (67 ± 14.2 mmol/mol) at 52 ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-06-01T10:16:56.174Z","creation":"2025-07-10T03:09:08.22Z"},"accession":"S-EPMC12016685","cross_references":{"pubmed":["40303270"],"doi":["10.1155/2023/6718115"]}}